IDiyas

For the Inventor, By the Inventor

Birchington, United Kingdom

David Alker

USPTO Granted Patents = 23

Average Co-Inventor Count = 2.8

ph-index = 8

Forward Citations = 184(Granted Patents)


Location History:

  • Eastry, Nr. Deal, GB (1985 - 1986)
  • Eastry, GB (1986 - 1987)
  • Margate, GB (1988 - 1990)
  • Birchington, GB (1990 - 1997)
  • Sandwich, GB (1994 - 2002)

Company Filing History:

goldMedal22 out of 4,455 
 
Pfizer Corporation
 patents
silverMedal1 out of 832,680 
Other
 patents

Years Active: 1985-2002

Loading Chart...
23 patents (USPTO):Explore Patents
1. 6380396 - Quaternary ammonium compounds (2002-04-30),
2. 6262046 - Azetidinylpropylpiperidine derivatives, intermediates and use as tachykinin antagonists (2001-07-17),
3. 6207678 - Quaternary ammonium compounds as tachykinin antagonists (2001-03-27),
4. 5607950 - Muscarinic receptor antagonists (1997-03-04),
5. 5534626 - 1-arylethyl-3-substituted piperidines (1996-07-09),
6. 5486527 - Anticholinergic agents (1996-01-23),
7. 5418229 - Muscarinic receptor antagonists (1995-05-23),
8. 5410046 - 1-arylethyl-3-substituted piperidines (1995-04-25),
9. 5397800 - Certain 1-azabicyclo[2.2.1]heptanes useful as muscarinic receptor (1995-03-14),
10. 5358953 - Imidazopyridine PAF/H.sub.1 antagonists (1994-10-25),
11. 5344835 - Piperidine and pyrrolidine derivatives (1994-09-06),
12. 5231104 - 1-arylethyl-3-substituted piperidines (1993-07-27),
13. 5192765 - Certain amines which are muscarinic receptor antagonists (1993-03-09),
14. 5089505 - 1-arylethyl-3-substituted piperidines (1992-02-18),
15. 5071844 - 5,11-dihydrodibenzo[b,e][1,4]-thiazepines useful as gastro intestinal (1991-12-10),

Title: The Innovative Contributions of David Alker: A Patent Profile

Introduction: David Alker, based in Birchington, GB, is a notable inventor with an impressive portfolio of 23 patents. His innovative work primarily focuses on pharmaceutical compounds and their applications in medicinal chemistry.

Latest Patents: Among his latest patents, David Alker has developed quaternary ammonium compounds, specifically Azetidinylpropylpiperidine derivatives. These compounds are recognized for their potential use as tachykinin antagonists, contributing valuable insights into the field of drug discovery.

Career Highlights: Throughout his career, David has contributed his expertise to leading organizations in the pharmaceutical industry, including Pfizer Corporation. His work has significantly advanced the field of medicinal chemistry and drug development, showcasing his commitment to innovation.

Collaborations: David has collaborated with other esteemed scientists in his field, including Peter E. Cross and Simon F. Campbell. These collaborations have fostered an environment of creativity and innovation, enabling the development of groundbreaking pharmaceutical solutions.

Conclusion: David Alker’s work and accomplishments demonstrate the impact of his contributions to science and innovation. With a strong foundation in drug discovery and a robust patent portfolio, he continues to be a prominent figure in the landscape of pharmaceutical invention.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…